SAN DIEGO and TORONTO, Oct. 22, 2019 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and address unmet medical needs of patients with life-threatening hematologic cancers, will release its financial results for the second quarter ended September 30, 2019 on Tuesday, November 5, 2019 after the close of the market.?
News
Aptose Biosciences Announces Results of Annual Meeting of Shareholders
SAN DIEGO and TORONTO, June 02, 2020 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of can… […]
News
Aptose to Release Second Quarter Ended June 30, 2020 Financial Results and Hold Conference Call on August 4, 2020
SAN DIEGO and TORONTO, July 21, 2020 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financ… […]
News
Aptose to Participate in Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies
SAN DIEGO and TORONTO, Sept. 16, 2019 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (?Aptose? or the ?Company?) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of ca… […]
